Overview

• The vaccine focuses on sarbecoviruses, including those responsible for COVID-19, SARS, and potential future strains.
• Utilizes 'protein superglue' to combine multiple viral components, enhancing its ability to preempt unknown viruses.
• Proven effective in mice, the vaccine generates broad immune responses, even in subjects previously exposed to SARS-CoV-2.
• Streamlined production process promises easier and faster large-scale manufacturing.
• Next steps include human trials and expanding the technology to other virus families with pandemic potential.